Skip to main content
Publish date:

Data Boost CombinatoRx

The stock is up 18% after positive trial results.

Shares of

CombinatoRx

(CRXX)

soared Monday after the biopharmaceutical company announced positive trial results on an experimental rheumatoid arthritis drug.

TheStreet Recommends

Recently, the stock was up $1.30, or 18.4%, to $8.35.

The trial compared a treatment dubbed CRx-102, plus a disease-modifying antirheumatic drug, with the disease-modifying drug and a placebo. Patients getting CRx-102 had statistically significant improvements in their disease after 42 days of treatment.

CRx-102 is combination of the cardiovascular drug dipyridamole and a low dose of the steroid prednisolone.